Nonsteroidal Anti-inflammatory Drugs and the Risk of Barrett's Esophagus

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 11, 2014, Pages 1832-1839.e6

  Khalaf, Natalia ^a,b   Nguyen, Theresa ^a,b   Ramsey, David ^a,b   El Serag, Hashem B ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Barrett's Esophagus; Esophageal Adenocarcinoma; Nonsteroidal Anti inflammatory Drugs; Risk Factors

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG USE; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS DYSPLASIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIMARY MEDICAL CARE; RISK REDUCTION; SELF REPORT; SMOKING; TREATMENT DURATION; AGED; CASE CONTROL STUDY; MIDDLE AGED; RISK ASSESSMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 84908241515     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.04.027     Document Type: Article

References (37)

1. Sharma P. Clinical practice. Barrett's esophagus. NEngl J Med 2009, 361:2548-2556.
2. Murray L., Watson P., Johnston B., et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003, 327:534-535.
3. Sikkema M., de Jonge P.J., Steyerberg E.W., et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244.
4. Spechler S.J. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013, 310:627-636.
5. Rastogi A., Puli S., El-Serag H.B., et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008, 67:394-398.
6. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091. American Gastroenterological Association.
7. Gonzalez-Perez A., Garcia Rodriguez L.A., Lopez-Ridaura R. Effects of nonsteroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003, 3:28.
8. Harris R.E., Beebe-Donk J., Doss H., et al. Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005, 13:559-583.
9. Rothwell P.M., Wilson M., Elwin C.-E., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
10. Duan L., Wu A.H., Sullivan-Halley J., et al. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2008, 17:126-134.
11. Sadeghi S., Bain C.J., Pandeya N., et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 2008, 17:1169-1178.
12. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
13. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
14. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
15. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
16. Schottenfeld D., Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006, 56:69-83.
17. Garcia J.M., Splenser A.E., Kramer J., et al. Circulating inflammatory cytokines and adipokines are associated with Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014, 12:229-238.
18. Kramer J.R., Fischbach L.A., Richardson P., et al. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol 2013, 11:373-381.
19. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
20. Vane J.R., Botting R.M. The mechanism of action of aspirin. Thromb Res 2003, 110:255-258.
21. Husain S.S., Szabo I.L., Tarnawski A.S. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002, 97:542-553.
22. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
23. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anti-cancer agents: mechanistic, pharmacologic, and clinical issues. JNatl Cancer Inst 2002, 94:252-266.
24. Lagorce C., Paraf F., Vidaud D., et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003, 42:457-465.
25. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: exvivo induction by bile salts and acid exposure. Gastroenterology 2000, 118:487-496.
26. Morris C.D., Armstrong G.R., Bigley G., et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001, 96:990-996.
27. Kandil H.M., Tanner G., Smalley W., et al. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001, 46:785-789.
28. Wilson K.T., Fu S., Ramanujam K.S., et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998, 58:2929-2934.
29. Zimmermann K.C., Sarbia M., Weber A.A., et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999, 59:198-204.
30. Kastelein F., Spaander M.C., Biermann K., et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011, 141:2000-2008. Probar-study Group.
31. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138:2260-2266.
32. Vaughan T.L., Dong L.M., Blount P.L., et al. Nonsteroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005, 6:945-952.
33. Omer Z.B., Ananthakrishnan A.N., Nattinger K.J., et al. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012, 10:722-727.
34. Anderson L.A., Johnston B.T., Watson R.G.P., et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006, 66:4975-4982.
35. Thrift A.P., Pandeya N., Smith K.J., et al. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther 2011, 34:1235-1244.
36. Lin D., Kramer J.R., Ramsey D., et al. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol 2013, 108:1576-1583.
37. Anderson L.A., Watson R.G., Murphy S.J., et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007, 13:1585-1594.